Latest Pharma Insights
Kyowa Kirin Discontinues Rocatinlimab Trials Due To Malignancy Risk
Kyowa Kirin halts all trials with its OX40-targeting antibody rocatinlimab following Kaposi’s sarcoma cases and Amgen's recent return of the asset.
Scrip - March 4, 2026
Kyowa Kirin halts all trials with its OX40-targeting antibody rocatinlimab following Kaposi’s sarcoma cases and Amgen's recent return of the asset.
Scrip - March 4, 2026
Sanofi Replenishes cGVHD Pipeline With Sino Biopharm’s JACK/ROCK Inhibitor
Deal Snapshot: By paying Sino Biopharm up to $1.5bn, Sanofi appears to planning for its new Chinese partner’s JACK/ROCK inhibitor rovadicitinib to pick up where its own Rezurock left off in first-line, chronic graft-versus-host disease.
Scrip - March 4, 2026
Deal Snapshot: By paying Sino Biopharm up to $1.5bn, Sanofi appears to planning for its new Chinese partner’s JACK/ROCK inhibitor rovadicitinib to pick up where its own Rezurock left off in first-line, chronic graft-versus-host disease.
Scrip - March 4, 2026
US FDA Sets Stage For Input On Supplement Industry’s ‘New Technologies And Approaches’
Industry groups acknowledge a March 27 public meeting has potential to influence how firms can expand product lines with additional ingredients and formulations allowed under DSHEA. FDA acknowledges industry’s interest in introducing additional ingredients.
HBW Insight - March 4, 2026
Industry groups acknowledge a March 27 public meeting has potential to influence how firms can expand product lines with additional ingredients and formulations allowed under DSHEA. FDA acknowledges industry’s interest in introducing additional ingredients.
HBW Insight - March 4, 2026
Beiersdorf ‘Rebalancing’ Nivea As Global Skin Market Weakness, China Reset, Dampen Brand Sales
German company Beiersdorf AG has launched an initiative to strategically 'rebalance' its Nivea skin care brand to return it to an ‘elevated growth trajectory.’
HBW Insight - March 4, 2026
German company Beiersdorf AG has launched an initiative to strategically 'rebalance' its Nivea skin care brand to return it to an ‘elevated growth trajectory.’
HBW Insight - March 4, 2026
Kyowa Kirin Discontinues Rocatinlimab Trials Due To Malignancy Risk
Kyowa Kirin halts all trials with its OX40-targeting antibody rocatinlimab following Kaposi’s sarcoma cases and Amgen's recent return of the asset.
Scrip - March 4, 2026
Kyowa Kirin halts all trials with its OX40-targeting antibody rocatinlimab following Kaposi’s sarcoma cases and Amgen's recent return of the asset.
Scrip - March 4, 2026
Sanofi Replenishes cGVHD Pipeline With Sino Biopharm’s JACK/ROCK Inhibitor
Deal Snapshot: By paying Sino Biopharm up to $1.5bn, Sanofi appears to planning for its new Chinese partner’s JACK/ROCK inhibitor rovadicitinib to pick up where its own Rezurock left off in first-line, chronic graft-versus-host disease.
Scrip - March 4, 2026
Deal Snapshot: By paying Sino Biopharm up to $1.5bn, Sanofi appears to planning for its new Chinese partner’s JACK/ROCK inhibitor rovadicitinib to pick up where its own Rezurock left off in first-line, chronic graft-versus-host disease.
Scrip - March 4, 2026
Nutromics Targets Vancomycin’s Dosing Blind Spot With Continuous Drug-Monitoring Patch
Nutromics’ wearable microneedle patch seeks to provide continuous drug monitoring in acute care patients starting with the hard-to-dose antibiotic vancomycin.
Medtech Insight - March 3, 2026
Nutromics’ wearable microneedle patch seeks to provide continuous drug monitoring in acute care patients starting with the hard-to-dose antibiotic vancomycin.
Medtech Insight - March 3, 2026
CMS Fraud Crackdown, Part 2: Agency Seeking Stakeholder Feedback To Help ‘CRUSH’ Medicare Fraud
CMS is asking stakeholders to help the agency craft potential regulatory changes aimed at bolstering its efforts to combat Medicare and Medicaid fraud. The agency has provided several topics to help guide stakeholder engagement.
Medtech Insight - March 3, 2026
CMS is asking stakeholders to help the agency craft potential regulatory changes aimed at bolstering its efforts to combat Medicare and Medicaid fraud. The agency has provided several topics to help guide stakeholder engagement.
Medtech Insight - March 3, 2026
RadNet’s $270M Gleamer Buy Takes Aim At GE HealthCare’s AI Ambitions
RadNet's CEO Berger sees little overlap with GE's Intelerad deal, which he argues is a PACS viewer – not a true AI rival. DeepHealth, he believes, has the potential to transform the radiology workflow.
Medtech Insight - March 3, 2026
RadNet's CEO Berger sees little overlap with GE's Intelerad deal, which he argues is a PACS viewer – not a true AI rival. DeepHealth, he believes, has the potential to transform the radiology workflow.
Medtech Insight - March 3, 2026
US FDA Sets Stage For Input On Supplement Industry’s ‘New Technologies And Approaches’
Industry groups acknowledge a March 27 public meeting has potential to influence how firms can expand product lines with additional ingredients and formulations allowed under DSHEA. FDA acknowledges industry’s interest in introducing additional ingredients.
HBW Insight - March 4, 2026
Industry groups acknowledge a March 27 public meeting has potential to influence how firms can expand product lines with additional ingredients and formulations allowed under DSHEA. FDA acknowledges industry’s interest in introducing additional ingredients.
HBW Insight - March 4, 2026
Beiersdorf ‘Rebalancing’ Nivea As Global Skin Market Weakness, China Reset, Dampen Brand Sales
German company Beiersdorf AG has launched an initiative to strategically 'rebalance' its Nivea skin care brand to return it to an ‘elevated growth trajectory.’
HBW Insight - March 4, 2026
German company Beiersdorf AG has launched an initiative to strategically 'rebalance' its Nivea skin care brand to return it to an ‘elevated growth trajectory.’
HBW Insight - March 4, 2026
Meet The New Boss, Same As The Old Boss: Hikma Sticks With Darwazah As CEO
Following the departure of Hikma’s former CEO Riad Mishlawi at the end of last year, the company’s chair Said Darwazah has once again taken on the chief executive role for the next two years, amid a slew of other management changes.
Generics Bulletin - March 3, 2026
Following the departure of Hikma’s former CEO Riad Mishlawi at the end of last year, the company’s chair Said Darwazah has once again taken on the chief executive role for the next two years, amid a slew of other management changes.
Generics Bulletin - March 3, 2026
‘The Pirates All Know Where The Treasure Is’ – Staying Ahead Of The Competition In US Biosimilars
At the AAM’s Access! 2026 conference, a dedicated panel on the latest developments for biosimilars discussed challenges and opportunities in the US market, predicting consolidation among current players as well as calling for policies that put biosimilars first.
Generics Bulletin - March 3, 2026
At the AAM’s Access! 2026 conference, a dedicated panel on the latest developments for biosimilars discussed challenges and opportunities in the US market, predicting consolidation among current players as well as calling for policies that put biosimilars first.
Generics Bulletin - March 3, 2026
Natco, Breckenridge Confirm US Pomalidomide Entry With Shared Exclusivity
Natco and US partner Breckenridge have launched generic pomalidomide in the US, targeting a $3.2bn market. The firms believe they have 180 days of shared exclusivity, strengthening Natco’s oncology portfolio.
Generics Bulletin - March 3, 2026
Natco and US partner Breckenridge have launched generic pomalidomide in the US, targeting a $3.2bn market. The firms believe they have 180 days of shared exclusivity, strengthening Natco’s oncology portfolio.
Generics Bulletin - March 3, 2026
Fresenius Kabi Bets On Volume Growth To Drive 2026 Margin Expansion
Kabi targets mid- to high-single-digit growth and a 16.5%-17% EBIT margin in 2026, raising its long-term ambition as it pivots toward biopharma and innovation – while warning margin gains hinge on volume ramp and operating leverage.
Generics Bulletin - March 3, 2026
Kabi targets mid- to high-single-digit growth and a 16.5%-17% EBIT margin in 2026, raising its long-term ambition as it pivots toward biopharma and innovation – while warning margin gains hinge on volume ramp and operating leverage.
Generics Bulletin - March 3, 2026
Headlamp Health’s Lumos AI Targets Cause Of CNS Trial Failure
Headlamp Health's Lumos AI uses a ‘neurosymbolic’ multi-agent framework to improve CNS trial patient selection, targeting the heterogeneity that drives neuroscience's high attrition rate.
In Vivo - March 3, 2026
Headlamp Health's Lumos AI uses a ‘neurosymbolic’ multi-agent framework to improve CNS trial patient selection, targeting the heterogeneity that drives neuroscience's high attrition rate.
In Vivo - March 3, 2026
Praxis Eyes Blockbuster Future As Precision Neurology Pipeline Matures
Praxis Precision Medicines is planning to shift from a clinical-stage company to a competitive commercial player in CNS, with the potential to launch multiple blockbuster medicines in the near future.
In Vivo - March 3, 2026
Praxis Precision Medicines is planning to shift from a clinical-stage company to a competitive commercial player in CNS, with the potential to launch multiple blockbuster medicines in the near future.
In Vivo - March 3, 2026